You are currently viewing a new version of our website. To view the old version click .

RNA Drugs in Tumor Microenvironment

This special issue belongs to the section “Tumor Microenvironment“.

Special Issue Information

Dear Colleagues,

The presence of a complex tumor microenvironment (TME) is recognized to play a crucial role in tumor progression, resistance to therapy, and spreading across the major cancer types, emphasizing the need of precise-targeting therapeutic molecules.

Indeed, RNA-drugs—including siRNAs, miRNAs/antimiRs, lncRNAs, RNA guides (gRNAs), saRNAs, aptamers and ASOs—are emerging as new classes of precise and safe therapeutic drugs for several undruggable disorders, including cancer. On the other hand, several extracellular ncRNAs have recently been implicated in cancer intracellular communication and in TME–tumor interplay.

As such, this Special Issue is intended to highlight the recent advances in understanding the TME–tumor interplay and to underscore the advantages and limitations of using RNA-based therapeutics to target the TME.

Dr. Vittorio de Franciscis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy
  • exosome
  • RNA therapeutic
  • tumor microenvironment
  • Tumor associated macrophage
  • Cancer Associated fibroblast
  • ncRNA
  • extracellular RNA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694